AUROBINDO PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 21.6%

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 21.6%
Wed, 14 Nov

AUROBINDO PHARMA has announced its results for the quarter ended September 2018. Here is a detailed performance review of the same:

AUROBINDO PHARMA Quarterly Financials

No. of Mths
Qtr. Ending
3
Sep-17*
3
Jun-18*
3
Sep-18*
QoQ ChangeYoY Change
Net SalesRs m44,35942,50347,51411.8%7.1%
Other incomeRs m103437263-39.9%155.7%
TurnoverRs m44,46242,94047,77711.3%7.5%
ExpensesRs m33,19035,39237,6516.4%13.4%
Gross profitRs m11,1697,1119,59434.9%-14.1%
DepreciationRs m1,3211,5451,6375.9%23.9%
InterestRs m17329535419.8%104.9%
Profit before taxRs m9,7785,7077,86637.8%-19.6%
TaxRs m1,9801,1551,75451.8%-11.4%
Profit after taxRs m7,7984,5526,11234.3%-21.6%
Gross profit margin%25.216.720.2
Effective tax rate%20.220.222.3
Net profit margin%17.510.612.8
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Reports, Regulatory Filings, Equitymaster


Year-on-Year Performance:
  • The company's operating income during the quarter grew 7.1% on a year-on-year (YoY) basis. The expenses were up by 13.4% YoY during the same period.
  • The company's operating profit declined by 14.1% YoY during the quarter. Consequently, operating profit margins witnessed a decline and stood at 20.2% in 2QFY19 as against 25.2% in 2QFY18.
  • Depreciation charges increased by 23.9% and finance costs increased by 104.9% YoY, respectively.
  • Other income increased by 155.7% YoY during the quarter.
  • Net profit for the quarter declined by 21.6% YoY. Net profit margins during the quarter declined from 17.5% in 2QFY18 to 12.8% in 2QFY19.
Quarter-on-Quarter Performance:
  • The company's operating income during the quarter grew 11.8% on a quarter-on-quarter (QoQ) basis. The expenses were up by 6.4% QoQ during the same period.
  • The company's operating profit increased by 34.9% QoQ during the quarter. Consequently, operating profit margins witnessed a growth and stood at 20.2% in 2QFY19 as against 16.7% in 1QFY18.
  • Net profit for the quarter increased by 34.3% QoQ, while net profit margins increased from 10.6% in 1QFY18 to 12.8% in 2QFY19.

To see how AUROBINDO PHARMA has performed over the last eight quarters, please visit here.

AUROBINDO PHARMA Share Price Performance

Over the last one year, AUROBINDO PHARMA share price has moved up from Rs 700.6 to Rs 772.3, registering a Gain of Rs 71.7 or around 10.2%.

Meanwhile, the S&P BSE HEALTHCARE Index is trading at Rs 14,316.1 (down 1.1%). Over the last one year it has moved up from 13,727.7 to 14,316.1, a gain of 588 points (up 4.3%).

Overall, the S&P BSE SENSEX is up 6.5% over the year.

Current Valuations

At the current price of Rs 772.3, the price to earnings (P/E) ratio of AUROBINDO PHARMA stands at 20.6 times its trailing twelve months earnings, while its price to book value (P/BV) ratio stands at 3.9 times.

Equitymaster requests your view! Post a comment on "AUROBINDO PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 21.6%". Click here!

  

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 38.6% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 38.6% YoY). Sales on the other hand came in at Rs 54 bn (up 28.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 10.9% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 10.9% YoY). Sales on the other hand came in at Rs 53 bn (up 30.7% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of AUROBINDO PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Sep 20, 2019 12:51 PM

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 5-YR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS